Date: 2014-12-16
Type of information: Plant acquisition
Acquired company: Baxter\'s Vero cell technology and related assets, including its production facility (USA - IL)
Acquiring company: Nanotherapeutics (USA - Fl)
Amount: undisclosed
Terms: * On December 15, 2014, Baxter International announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic , to Nanotherapeutics, Inc. Financial details were not disclosed. In recent weeks, the company has also completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer. \'\'The divestiture of the vaccines franchise will allow Baxter BioScience to enhance focus in core therapeutic areas of hematology, oncology and immunology, as it prepares to become an independent biopharmaceutical company,\'\' said Ludwig Hantson , Ph.D., president of Baxter BioScience.
Details: The Vero cell platform is an advanced, cell-based technology for vaccines production. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus.
Related: Vaccines Infectious diseases
